Area of research
Hematology · Neurology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Neuroblastoma Research and Treatments, Acute Lymphoblastic Leukemia research, and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis.
Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Addressing Knowledge Gaps in the Early Detection of Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: An Official American Thoracic Society Research Statement
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease
Noninfectious pulmonary complications after hematopoietic cell transplantation: a comprehensive review
Addressing Knowledge Gaps in the Early Detection of Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: An Official American Thoracic Society Research Statement.
Inflammatory Markers and Microbiome Dysbiosis in Hematopoietic Cell Transplant Recipients with Lung Graft-versus-Host Disease
Detection of Bronchiolitis Obliterans Syndrome after Pediatric Hematopoietic Stem Cell Transplantation: An Official American Thoracic Society Clinical Practice Guideline
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
Prognostic Value of Elafin in Acute Graft-Versus-Host Disease
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
First-Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell Transplantation.
Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD